[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100392952":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":10,"locations":19,"responsibleParty":32,"collaborators":10,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":10,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":10,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":10,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Ipsen","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Botox",null,"all eligible subjects, in a reverse consecutive order, initiated on onaBoNT-A from 01 March 2015 to 29 May 2017.",{"label":13,"type":10,"description":14,"interventionNames":10},"Dysport","all subjects meeting inclusion\u002Fexclusion criteria and initiated on aboBoNT-A from 30 May 2017 to 30 March 2019.",[16],{"name":17,"affiliation":5,"role":18},"Ipsen Medical Director","STUDY_DIRECTOR",[20],{"facility":21,"status":10,"city":22,"state":10,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":10},"North Staffordshire Rehabilitation Centre. Midlands Partnership NHS Foundation Trust.","Stafford","ST6 7AG","United Kingdom","UK",{"type":27,"coordinates":28},"Point",[29,30],-2.11636,52.80521,{"lat":30,"lon":29},{"type":33,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100392952","a-study-to-assess-treatment-outcomes-of-abobotulinumtoxina-and-onabotulinumtoxina-treatments-in-real-life-practice-in-toxin-nave-adult-patients-with-limb-spasticity-100392952",false,"NCT04396704","A Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.","A Single Centre, Non-interventional, Retrospective Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.","Inclusion Criteria :\n\n* Patient diagnosed with spasticity related to any cause except cerebral palsy.\n* Patient initiated on treatment with either onaBoNT-A or aboBoNT-A during the study enrolment periods.\n* Patient is an adult aged ≥18 years old at the time of the first BoNT-A injection for spasticity\n* Patient has not received treatment with any type of BoNT-A 6 months prior to initiation of onaBoNT-A or aboBoNT-A. For patients with multiple courses of BoNT-A, separated by a gap of 6 months, only the first course will be evaluated in this study.\n* Patient is being treated at Haywood Hospital at index date and during follow-up for up to 24 weeks post-index date, with medical records available for review.\n\nExclusion Criteria :\n\n* Patient is participating in an interventional clinical trial of an investigational medicinal product for the treatment of spasticity at index date and\u002For during follow-up.","ALL","18 Years",{"count":44,"type":45},114,"ACTUAL","OBSERVATIONAL","The aim of the study is to describe treatment outcomes of abobotulinumtoxinA (aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A) treatments, after one injection of either treatment, in toxin-naïve adult patients with upper and\u002For lower limb spasticity at a single National Health Service (NHS) centre in the United Kingdom (UK).",[49],"Spasticity Related to Any Cause Except Cerebral Palsy","COMPLETED","2021-05-20",{"date":53,"type":45},"2021-05-21",{"date":55,"type":45},"2021-01-11",{"date":57,"type":45},"2021-03-30",{"name":5,"class":6},1]